Savana raises €3.8M in series A financing led by for international expansion —
Summary
The main reason for this is the exhaustion of a model based on broad indications, while the unstructured free-text content of electronic health records has remained untapped. Savana has identified this huge opportunity and developed a proprietary technology platform that can understand and extract insights from doctor’s notes in free text. The company’s products have enabled hospitals to extract insights from doctor’s notes for the first time to optimise their operations and boost research and innovation in clinical practice. Jorge Tello Guijarro, Savana’s CEO and one of its co-founders, commented: “This new investment will help us achieve our mission to revolutionise how the unstructured free-text content of health records is used in clinical research, improving healthcare systems and fostering personalised medicine. The next product in the pipeline is Savana Predict, which is also based on proprietary technology (‘Entropia’), which will advance disease diagnosis for each patient, revolutionising medical practice worldwide.